Enicepatide: a renamed program enters a broader obesity portfolio
Enicepatide connects several names in one development story: CT-388, RO7795068 and RG6640.
Enicepatide connects several names in one development story: CT-388, RO7795068 and RG6640. Roche's current program includes weekly injected treatment in obesity and a study in people with type 2 diabetes. The compound remains investigational. A September 22 Phase 2 update adds diabetes-population evidence and is examined in a separate dated entry. Roche update.
The ENITH Phase 3 records distinguish participants with and without type 2 diabetes, use placebo control, and assess weight change at 72 weeks. Both records were recruiting when retrieved. These prospective designs explain what the next development stage is intended to establish; recruitment status alone says nothing about the outcome. NCT07351045, NCT07351058.
Roche acquired the program through Carmot. Its partnership with Zealand also creates a combination path involving petrelintide. The combination trial retains two compound identities, rather than inventing a new name for either constituent. Its separate comparison groups matter when asking what each component contributes. Combination study, ownership and partnership history (below).
The competitive setting includes approved incretin treatments and other investigational mechanisms. Results from a diabetes population over 48 weeks should not be ranked directly against longer trials excluding diabetes. Current evidence also leaves longer-term tolerability and outcome questions. Roche's financial context (below) describes corporate funding capacity; neither the Carmot acquisition price nor the Zealand agreement's headline value is a disclosed budget for enicepatide alone.
Roche — company resources
Roche reported CHF 5.448 billion of cash and equivalents and CHF 4.286 billion of other marketable liquidity at June 30, a combined CHF 9.734 billion. Total debt was CHF 31.805 billion; the company's net-debt measure was CHF 22.071 billion. First-half operating cash flow was CHF 7.635 billion and IFRS net income CHF 7.325 billion. The profitable group can fund research from operating businesses, but these figures do not disclose a dedicated budget for either obesity program. Its CHF 4.197 billion free-cash-flow measure is distinct from operating cash flow. Half-year report published July 23.
Roche and Zealand — petrelintide and combination development
The collaboration was announced in March 2025 and became effective in May. Zealand received $1.4 billion upfront in the second quarter of 2025. A further $250 million is scheduled across two anniversaries; the first $125 million was received in the first half of 2026. Potential development and sales milestones total up to $1.2 billion and $2.4 billion respectively and remain contingent.
The partners share profits and losses equally in the United States and Europe, with co-commercialization rights. Roche has exclusive commercialization rights elsewhere, where Zealand is eligible for tiered double-digit royalties reaching the high teens. Roche carries commercial manufacturing investment responsibilities. The program includes petrelintide alone and combinations with Roche's enicepatide; the agreement's aggregate economics should not be assigned wholly to the combination or treated as cash reserved for a single trial. Zealand 2025 annual report, partnership account, 2026 half-year cash receipt.
Roche and Carmot — acquisition and enicepatide
Roche's December 2023 acquisition announcement identified CT-388 among several Carmot clinical programs. The announced consideration included an upfront purchase price and contingent milestones. That portfolio transaction should not be reported as a compound-specific research allocation. Current Roche releases identify CT-388 as enicepatide, while registry records also retain RO7795068. Keeping those names connected prevents an ownership change from appearing to create a new compound. Roche acquisition announcement, Roche development update, September 22, 2026.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.